Aytu BioPharma Launches EXXUA for Major Depressive Disorder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy AYTU?
Aytu BioPharma announced the nationwide commercial launch of EXXUA and completion of its launch meeting last week that finalized sales training and launch preparations for EXXUA, the first and only selective 5-HT1A agonist approved by the United States Food and Drug Administration for the treatment of major depressive disorder in adults, representing a new way to treat MDD. EXXUA is a once-daily monotherapy with a unique mechanism of action that selectively targets 5-HT1A receptors, important regulators of mood and emotion while minimizing activity at serotonin receptors linked to side effects such as sexual dysfunction and weight gain that are common with many first-line antidepressants. EXXUA is only approved for use in adults. Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AYTU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AYTU
Wall Street analysts forecast AYTU stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.270
Low
7.00
Averages
9.33
High
13.00
Current: 2.270
Low
7.00
Averages
9.33
High
13.00
About AYTU
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aytu BioPharma Q3 2026 Earnings Call Insights
- Prescription Growth: In Q3 2026, prescriptions for EXXUA surged from approximately 200 in January to over 920 in April, indicating increasing market acceptance and potential for future sales growth.
- Financial Performance Fluctuations: The company reported net revenue of $12.4 million for the third quarter, down from $18.5 million year-over-year, despite the ADHD portfolio contributing $9.1 million, reflecting intensified market competition and pricing pressures.
- Marketing Spend Plans: Aytu plans to increase marketing expenditures by $1 million to $2 million in Q4 to support online promotional activities, which is expected to enhance brand visibility and market penetration.
- Improving Market Access: Management highlighted early positive signs in coverage and reimbursement rates across both commercial and government payer channels, suggesting that market access for EXXUA is gradually improving, which could drive future sales growth.
See More
Aytu BioPharma Reports Strong Initial Traction for Exua in Q3 Earnings
- Prescription Growth: Aytu BioPharma reported over 1,300 prescriptions for Exua in Q3, indicating early adoption by physicians, with a notable 26% month-over-month growth from March to April, reflecting increasing market demand.
- Effective Market Strategy: The company's focused and disciplined launch strategy targeting high-prescribing psychiatry practices is yielding positive results, further solidifying its position in the major depressive disorder treatment market.
- Positive Patient Feedback: Patient feedback for Exua has been overwhelmingly positive, with many reporting life-changing experiences, suggesting that the drug meets a significant unmet need in the treatment of major depressive disorder.
- Financial Challenges: Despite the strong performance of Exua, the company faced a 33% year-over-year decline in net revenue for Q3, primarily due to a strategic shift and generic competition, resulting in a net loss of $5.6 million, indicating increasing financial pressure.
See More
Aytu BioPharma Q3 Earnings Announcement Scheduled
- Earnings Release Date: Aytu BioPharma is set to announce its Q3 earnings on May 13th after market close, drawing significant attention from investors regarding its performance amid current economic conditions.
- EPS Expectations: The consensus EPS estimate stands at -$0.51, reflecting a staggering 178.5% year-over-year decline, indicating substantial profitability pressures that could negatively impact investor confidence.
- Revenue Decline: The anticipated revenue for Q3 is $12.05 million, representing a 34.9% year-over-year drop, highlighting challenges in sales and market demand that may affect future liquidity.
- Estimate Revisions: Over the past three months, EPS estimates have seen one upward and one downward revision, while revenue estimates have not seen any upward revisions and have experienced two downward adjustments, suggesting instability in market expectations for the company's future performance.
See More
Aytu BioPharma Reports Q2 2026 Earnings with EXXUA Launch Insights
- EXXUA Launch Progress: Aytu BioPharma's EXXUA, the first FDA-approved 5HT1a agonist, has been prescribed in 27 states by over 100 physicians, indicating strong market demand and potential for sales growth.
- Revenue Performance: The company reported net revenue of $15.2 million for Q2, a decline from $16.2 million year-over-year, yet the ADHD portfolio's $13.2 million revenue demonstrates resilience, suggesting stability in a competitive market.
- Gross Margin Changes: Gross margin for the quarter was reported at 63.5%, down from 66.5% last year, primarily due to transition-related expenses and an inventory write-down of approximately $600,000, impacting overall profitability.
- Future Outlook: The company anticipates a slight increase in EXXUA net revenue in the March 2026 quarter, targeting breakeven at $17.3 million per quarter, reflecting management's confidence in future growth despite market challenges.
See More
Aytu BioPharma AYTU Q2 2026 Earnings Transcript
See More
Aytu BioPharma Q2 Earnings Analysis
- Earnings Performance: Aytu BioPharma reported a Q2 GAAP EPS of -$1.05, missing expectations by $0.45, indicating challenges in profitability that may affect investor confidence.
- Revenue Insights: The company generated $15.2M in revenue, a 6.3% year-over-year decline, yet exceeded market expectations by $3.03M, suggesting a resilient market demand despite challenges.
- Investment Strategy: Aytu BioPharma plans to invest $10M in the launch of EXXUA, aiming to enhance the performance of its ADHD product line and drive future revenue growth.
- Breakeven Target: The company has set a breakeven quarterly revenue target of $17.3M, indicating that achieving this goal will be crucial for the success of its future strategic initiatives.
See More
Aytu BioPharma Q3 2026 Earnings Call Insights
- Prescription Growth: In Q3 2026, prescriptions for EXXUA surged from approximately 200 in January to over 920 in April, indicating increasing market acceptance and potential for future sales growth.
- Financial Performance Fluctuations: The company reported net revenue of $12.4 million for the third quarter, down from $18.5 million year-over-year, despite the ADHD portfolio contributing $9.1 million, reflecting intensified market competition and pricing pressures.
- Marketing Spend Plans: Aytu plans to increase marketing expenditures by $1 million to $2 million in Q4 to support online promotional activities, which is expected to enhance brand visibility and market penetration.
- Improving Market Access: Management highlighted early positive signs in coverage and reimbursement rates across both commercial and government payer channels, suggesting that market access for EXXUA is gradually improving, which could drive future sales growth.
See More
Aytu BioPharma Reports Strong Initial Traction for Exua in Q3 Earnings
- Prescription Growth: Aytu BioPharma reported over 1,300 prescriptions for Exua in Q3, indicating early adoption by physicians, with a notable 26% month-over-month growth from March to April, reflecting increasing market demand.
- Effective Market Strategy: The company's focused and disciplined launch strategy targeting high-prescribing psychiatry practices is yielding positive results, further solidifying its position in the major depressive disorder treatment market.
- Positive Patient Feedback: Patient feedback for Exua has been overwhelmingly positive, with many reporting life-changing experiences, suggesting that the drug meets a significant unmet need in the treatment of major depressive disorder.
- Financial Challenges: Despite the strong performance of Exua, the company faced a 33% year-over-year decline in net revenue for Q3, primarily due to a strategic shift and generic competition, resulting in a net loss of $5.6 million, indicating increasing financial pressure.
See More
Aytu BioPharma Q3 Earnings Announcement Scheduled
- Earnings Release Date: Aytu BioPharma is set to announce its Q3 earnings on May 13th after market close, drawing significant attention from investors regarding its performance amid current economic conditions.
- EPS Expectations: The consensus EPS estimate stands at -$0.51, reflecting a staggering 178.5% year-over-year decline, indicating substantial profitability pressures that could negatively impact investor confidence.
- Revenue Decline: The anticipated revenue for Q3 is $12.05 million, representing a 34.9% year-over-year drop, highlighting challenges in sales and market demand that may affect future liquidity.
- Estimate Revisions: Over the past three months, EPS estimates have seen one upward and one downward revision, while revenue estimates have not seen any upward revisions and have experienced two downward adjustments, suggesting instability in market expectations for the company's future performance.
See More
Aytu BioPharma Reports Q2 2026 Earnings with EXXUA Launch Insights
- EXXUA Launch Progress: Aytu BioPharma's EXXUA, the first FDA-approved 5HT1a agonist, has been prescribed in 27 states by over 100 physicians, indicating strong market demand and potential for sales growth.
- Revenue Performance: The company reported net revenue of $15.2 million for Q2, a decline from $16.2 million year-over-year, yet the ADHD portfolio's $13.2 million revenue demonstrates resilience, suggesting stability in a competitive market.
- Gross Margin Changes: Gross margin for the quarter was reported at 63.5%, down from 66.5% last year, primarily due to transition-related expenses and an inventory write-down of approximately $600,000, impacting overall profitability.
- Future Outlook: The company anticipates a slight increase in EXXUA net revenue in the March 2026 quarter, targeting breakeven at $17.3 million per quarter, reflecting management's confidence in future growth despite market challenges.
See More
Aytu BioPharma AYTU Q2 2026 Earnings Transcript
See More
Aytu BioPharma Q2 Earnings Analysis
- Earnings Performance: Aytu BioPharma reported a Q2 GAAP EPS of -$1.05, missing expectations by $0.45, indicating challenges in profitability that may affect investor confidence.
- Revenue Insights: The company generated $15.2M in revenue, a 6.3% year-over-year decline, yet exceeded market expectations by $3.03M, suggesting a resilient market demand despite challenges.
- Investment Strategy: Aytu BioPharma plans to invest $10M in the launch of EXXUA, aiming to enhance the performance of its ADHD product line and drive future revenue growth.
- Breakeven Target: The company has set a breakeven quarterly revenue target of $17.3M, indicating that achieving this goal will be crucial for the success of its future strategic initiatives.
See More
